Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold ...

Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) had its target price lowered by equities researchers at Citigroup from ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Eli Lilly and Company discovers ... Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca ...

Eli Lilly is experiencing explosive growth thanks ... of this total stems from just three drugs -- Mounjaro, Zepbound, and Trulicity. All of these are medications in Lilly's weight loss portfolio.

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...